GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (NAS:ABEO) » Definitions » Book Value per Share

Abeona Therapeutics (Abeona Therapeutics) Book Value per Share : $-0.32 (As of Mar. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Book Value per Share?

Abeona Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $-0.32.

During the past 12 months, Abeona Therapeutics's average Book Value Per Share Growth Rate was -130.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -72.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -64.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Abeona Therapeutics was 146.80% per year. The lowest was -72.40% per year. And the median was -4.60% per year.

Abeona Therapeutics's current price is $4.05. Its book value per share for the quarter that ended in Mar. 2024 was $-0.32. Hence, today's PB Ratio of Abeona Therapeutics is .

During the past 13 years, the highest P/B Ratio of Abeona Therapeutics was 55.46. The lowest was 0.37. And the median was 2.09.


Abeona Therapeutics Book Value per Share Historical Data

The historical data trend for Abeona Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Book Value per Share Chart

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.34 26.67 7.20 1.51 0.56

Abeona Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 0.44 0.89 0.56 -0.32

Competitive Comparison of Abeona Therapeutics's Book Value per Share

For the Biotechnology subindustry, Abeona Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's PB Ratio falls into.



Abeona Therapeutics Book Value per Share Calculation

Abeona Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(14.83-0.00)/26.52
=0.56

Abeona Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-8.88-0.00)/27.55
=-0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Abeona Therapeutics  (NAS:ABEO) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Abeona Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics (Abeona Therapeutics) Business Description

Traded in Other Exchanges
Address
1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.
Executives
Mark Alvino director C/O SCO SECURITIES LLC, 1285 AVENUE OF THE AMERICAS 35TH FLOOR, NEW YORK NY 10019
Michael Amoroso officer: Chief Operating Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Vishwas Seshadri director, officer: Chief Executive Officer 64 STRYKER COURT, BRIDGEWATER NJ 08807
Leila Alland director C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Christine Berni Silverstein officer: Chief Financial Officer C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Joseph Walter Vazzano officer: Chief Financial Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Brendan M. O'malley officer: SVP, General Counsel 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Adage Capital Partners, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Management, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Partners Gp, L.l.c. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert Atchinson 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Phillip Gross 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Edward Carr officer: Vice President, Controller 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Todd Wider director 4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219